Literature DB >> 1930878

Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication.

S Lal1, N P Nair, J X Thavundayil, V Tawar, R Quirion, H Guyda.   

Abstract

The stereospecificity of the D-2 receptor mediating the growth hormone (GH) response to apomorphine (Apo) and the D-2 receptor regulating prolactin (PRL) secretion were investigated in 10 normal men by examining the effects of cis-flupenthixol (cis-Fx) and trans-flupenthixol (trans-Fx). cis-Fx (1 mg six hourly times four doses) antagonized the GH response to Apo HCl (0.5 mg sc) and increased basal serum PRL concentrations whereas the trans-isomer showed no effect. These findings (a) provide further evidence that the GH response to Apo is mediated by stimulating dopamine (DA) receptors, and, (b) demonstrate stereospecificity of the DA receptor mediating the GH response to Apo and the DA receptor regulating PRL secretion.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1930878     DOI： 10.1007/bf01244707

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  26 in total

1.  The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine studies in normal men.

Authors:  G Langer; E J Sachar; F S Halpern; P H Gruen; M Solomon
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

2.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

3.  Effect of apomorphine on human-growth-hormone secretion.

Authors:  S Lal; C E De la Vega; T L Sourkes; H G Friesen
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  Electroconvulsive therapy and the brain: evidence for increased dopamine-mediated responses.

Authors:  D W Costain; P J Cowen; M G Gelder; D G Grahame-Smith
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

6.  Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man.

Authors:  S Lal; N P Nair; H Eugenio; J Thavundayil; E Lizondo; P L Wood; P Etienne; H Guyda
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1983       Impact factor: 5.067

7.  Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.

Authors:  N P Nair; S Lal; P Cervantes; R Yassa; H Guyda
Journal:  Neuropsychobiology       Date:  1979       Impact factor: 2.328

Review 8.  Apomorphine in the evaluation of dopaminergic function in man.

Authors:  S Lal
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

9.  Effect of sleep deprivation on dopamine receptor function in normal subjects.

Authors:  S Lal; J Thavundayil; N P Nair; P Etienne; R Rastogi; G Schwartz; J Pulman; H Guyda
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Effect of lithium on hypothalamic-pituitary dopaminergic function.

Authors:  S Lal; N P Nair; H Guyda
Journal:  Acta Psychiatr Scand       Date:  1978-01       Impact factor: 6.392
View more
  3 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome.

Authors:  A Heinz; B Lichtenberg-Kraag; S S Baum; K Graf; F Kruger; M Dettling; H Rommelspacher
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects.

Authors:  S Lal; J X Thavundayil; B Krishnan; N P Nair; G Schwartz; H Guyda
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.